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Abstract
Background: Traditional methods of diagnosing mucosal leishmaniasis (ML), such as biopsy with histopathology, are
insensitive and require collection of an invasive diagnostic specimen.
Methods: We compared standard invasive procedures including biopsy histopathology, biopsy PCR, and leishmanin skin
test (LST) to a novel, non-invasive, cytology-brush based PCR for the diagnosis of ML in Lima, Peru. Consensus reference
standard was 2/4 tests positive, and outcome measures were sensitivity and specificity. Leishmania species identification
was performed by PCR-based assays of positive specimens.
Results: Twenty-eight patients were enrolled, 23 of whom fulfilled criteria for a diagnosis of ML. Sensitivity and specificity of
biopsy with histopathology were 21.7% [95% CI 4.9–38.5%] and 100%; 69.6% [95% CI 50.8–88.4%] and 100% for LST; 95.7%
[95% CI 87.4–100%] and 100% for biopsy PCR; and 95.7% [95% CI 87.4–100%] and 90% [95% CI 71.4–100%] for cytology
brush PCR using both CervisoftH and HistobrushH cervical cytology brushes. Represented species identified by PCR-RFLP
included: L. (V). braziliensis (n=4), and L. (V). peruviana (n=3).
Conclusions: Use of commercial grade cytology brush PCR for diagnosis of ML is sensitive, rapid, well tolerated, and carries
none of the risks of invasive diagnostic procedures such as biopsy. Further optimization is required for adequate species
identification. Further evaluation of this method in field and other settings is warranted.
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Introduction
Mucosal leishmaniasis (ML) is a severe and stigmatizing chronic
sequela of infection with predominantly New World species of
Leishmania including L. (Viannia) braziliensis [1–5]. Along with Brazil
and Bolivia, Peru contributes more than 90% of ML cases
worldwide [1]. Differentiating ML from other endemic etiologies
such as tuberculosis, non-tuberculous mycobacterial infections,
rhinoscleroma, paracoccidioidomycosis, and malignancy is diffi-
cult on clinical grounds as manifestations such as nasal injection,
pruritus, and infiltration, epistaxis, dysphonia, and palatal
infiltration may be common to all. Coupled with the highly toxic
nature of standard antimonial therapy, the broad differential
diagnosis of mucosal lesions in Peruvian patients necessitates the
use of accurate diagnostic modalities.
Traditional methods of diagnosing ML, such as biopsy with
histopathology, are insensitive and require collection of an invasive
diagnostic specimen [2,6]. Invasive specimen collection is difficult
to perform in remote under-resourced settings, and without
technical expertise [7–9]. While PCR is a highly sensitive
technique and is quickly becoming a favored ‘gold standard’ for
the diagnosis of leishmaniasis [6,10–14], this platform has mostly
been used on invasive diagnostic specimens in ML such as biopsies
[2,9,14]. Accurate diagnosis in the absence of a well-performing
gold standard is an ongoing challenge in leishmaniasis [15]. There
is therefore a need for sensitive, accurate non-invasive diagnostic
testing in ML.
We herein compared several ‘traditional’ methods for diagnos-
ing ML including biopsy with histopathology, biopsy PCR, and
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cytology brush PCR using 2 different commercial grade cervical
cytology brushes. In addition, we performed species identification
using PCR-based assays of clinical specimens, which is important
in countries like Peru where several members of the Leishmania
(Viannia) subgenus can cause mucosal disease.
Methods
Ethics Statement
This study was approved by the Institutional Review Boards of
Hospital Nacional Cayetano Heredia (HNCH) and the University
of Toronto. All patients provided written informed consent for the
study procedures prior to enrolment.
Study Site
The study was conducted at the Leishmania Clinic of the Instituto
de Medicina Tropical ‘‘Alexander Von Humboldt’’ and HNCH,
in Lima, Peru, between January and December 2010. The
Institute houses a large outpatient clinic for the diagnosis and
management of American tegumentary leishmaniasis, with an
average of 30–40 new cases diagnosed per month [7,16].
Study Population
Consecutive patients presenting to the Leishmania Clinic for the
evaluation of mucosal (nasal, buccal, oral, pharyngeal) and/or skin
lesions were approached to participate in this study, and screened
for eligibility criteria. All patients were interviewed and examined
by a clinic physician. Direct anterior rhinoscopy and orophar-
yngoscopy were performed on all patients (including those referred
for cutaneous ulcers), to determine if mucosal abnormalities such
as erythema, infiltration, or ulceration were present. We included
patients who were referred to the Leishmania Clinic for suspected
ML or CL; had one or more mucosal lesions with a clinical
indication for mucosal biopsy; and were able to give informed
consent for the diagnostic procedures. We excluded patients
undergoing active treatment for ML or CL, and those with any
contraindication to mucosal biopsy.
Sampling
Cytology brushes. After removing any overlying scab or
crust with moistened gauze, and cleansing the mucosal lesion with
isopropyl alcohol, sterile and duplicate CerviSoftH (Puritan
Medical Products, Maine) and HistobrushH (Puritan Medical
Products, Maine) cervical cytology brushes (Figure 1) were rolled
clockwise on the lesion 5 times each in sequence. Each cytology
brush has a cylindrical handle of several inches in length, and a
foam or bristled tip of 1-inch in length for collection of clinical
specimens (Figure 1). Cytology brush tips were then cut off with
sterile scissors directly into 1.5-mL Eppendorf tubes containing
700 mL 100% ethanol and stored at 220 C for qualitative PCR
testing. Control nasal septum and buccal cytology brush specimens
were collected and processed as above from 5 healthy volunteers
with normal mucosa living in a non-endemic area.
Mucosal biopsy. After collection of the cytology brush
specimens and cleansing the lesion again with isopropyl alcohol,
mucosal lesions were anesthetized with 20 mg/mL lidocaine
spray. Two small biopsy specimens were then obtained from
lesions using sterile nasal or ethmoid biopsy forceps. The tissue was
then stored in 1.5-mL Eppendorf tubes containing 700 mL 100%
ethanol at 220uC for qualitative PCR testing, or placed in 10%
formalin for histopathology with hematoxylin and eosin, Ziehl-
Neelsen, and Giemsa staining. Sterile gauze was applied with
pressure to the mucosal lesion until hemostasis was achieved.
Leishmanin Skin Test
Leishmanin skin tests were applied and read as described [7,16].
A positive result was indicated by $5 mm of erythema and
induration as previously described [7,16,17].
Isolation of DNA from Cytology Brushes and Biopsy
Specimens
Prior to DNA extraction, samples were centrifuged at 3000 g
for 5 min and ethanol was discarded. Biopsied tissues were
disaggregated with a sterile scalpel. Disaggregated tissue and
cytology brushes were processed for DNA isolation using the High
Pure PCR Template Preparation KitH (Roche, Mannheim,
Germany) according to manufacturer’s instructions.
Kinetoplastid DNA (kDNA) Polymerase Chain Reaction
Leishmania kDNA PCR was performed using the HotStar Taq
Plus DNA Polymerase kit (QIAGEN, Hilden, Germany) and
conditions were as described [7]. Two pairs of primers were used
as previously described [7,18]. Amplicons were visualized on 3%
agarose gels (Promega, Madrid, Spain) and stained with ethidium
bromide.
Species Identification by PCR and Restriction Fragment
Length Polymorphism (PCR-RFLP) of Genomic Targets
Four PCR assays targeting different sequences specific to
Leishmania sub-genus Viannia species including L. (V.) braziliensis,
L. (V.) peruviana, and L. (V.) guyanensis, the principal causative
species in Peru, were used for the species identification following
initial kDNA PCR. PCR assays were performed using the HotStar
Taq Plus DNA Polymerase kit (QIAGEN, Hilden, Germany) as
previously described [7].
The first assay, targeting the mannose phosphate isomerase gene
(MPI), consisted of two separate reactions employing allele-specific
reverse primers, which distinguish L. (V.) peruviana from L. (V.)
braziliensis and L. (V.) guyanensis, as previously described [7,19]. MPI
PCRconditionswereasdescribed[7,19].Thesecondassay,targeting
the cysteine proteinase B (Cpb) gene, employed primers which
distinguish between L. (V.) braziliensis and non-L. (V.) braziliensis
species as previouslydescribed [7,20,21]. CpbPCR conditions were as
described [7,20,21]. The third assay, targeting heat shock protein 70
(hsp70), employed primers which distinguish between L. (V.) guyanensis
and non-L. (V.) guyanensis species as previously described [7,21,22].
Hsp70 PCR conditions were as described [21,22].
A fourth and final PCR assay was used to confirm species on
those samples that yielded weak bands or lack of amplification
products in previous assays. The PCR target was a 870 bp
fragment of Leishmania glycoprotein of 63 kDa (gp63), with the
following primer sequences: MUS (fwd) 59- GTGGGTGTCAT-
CAACATCCC – 39 and MUSA3 (rev) 59- CTGCTGCCGTA-
CACCTGGAC – 39 [23]. Gp63 PCR conditions were as follows:
95uC for 5 min, followed by 45 cycles of denaturation at 94uC for
30 s; primer annealing at 63uC for 60 s; extension at 72uC for
60 s, and a final extension step at 72uC for 6 min (iCycler iQ, Bio-
Rad). All PCR products were visualized on 1.5% agarose gels
(Promega, Madrid, Spain) and stained with ethidium bromide.
Restriction fragment length polymorphism analysis of
Cpb, Hsp70, and gp63 PCR products (PCR-RFLP)
Following cpb, hsp70 and gp63 PCR amplification as above,
products were separately digested overnight at 65uC for the cpb
assay, or 37uC for the hsp70 and gp63 assay, in a total volume of
20 mL, with 5 U of each restriction enzyme. The following
enzymes were used in each reaction: TaqI( cpb) and HaeIII (hsp70)
Cytology Brush PCR for Leishmania Detection
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26395(Fermentas, Burlington, Canada). For gp63, products were digested
in duplicate. One reaction was digested with HincII and the second
with SalI restriction enzyme (Fermentas, Burlington, Canada).
Restriction fragments were then analyzed separately using 2.5%
agarose gels for cpb and gp63 or 4% agarose gels for hsp70
(Promega, Madrid, Spain), and stained with ethidium bromide.
When weak amplification product was observed after PCR,
restriction fragments were separated using 12% polyacrylamide
gel electrophoresis using the MiniProtean III system (Bio-Rad,
Hercules, CA, USA), and stained with silver stain (Promega,
Madrid, Spain). Mpi PCR distinguishes L. (V.) peruviana, while Cpb
PCR-RFLP distinguishes L. (V.) braziliensis, and hsp70 PCR-RFLP
differentiates L. (V.) guyanensis from L. (V.) lainsoni.
Composite Reference Standard
We defined a lesion as ML when any 2 of 4 tests were positive,
where tests refer to biopsy with histopathology; biopsy PCR; LST;
or cytology brush PCR. These 4 tests served as the composite
reference standard against which each individual diagnostic test
was compared. Assessors of LST, histopathology, and PCR were
blind to the results of the other assays.
Sample Size Calculation
Based on existing literature [2,14,24–26], we estimated the
overall sensitivity of gold standard biopsy with histopathology to be
40%, and the sensitivity of biopsy PCR to be 90–95%. In order to
achieve a sensitivity of cytology brush PCR better than the gold
standard histopathology and comparable to biopsy PCR, assuming
an a=0.05 and a power of 80%, 28 patients were required per
group. For sensitivity analysis, the aforementioned composite
reference standard was applied, and the unit of analysis was the
patient.
Statistical Analysis
Descriptive statistics (mean, SD, median, range) were calculated
for continuous variables, and differences were compared using 2-
Figure 1. Cervical cytology brushes. A, sterile wrapped CerviSoftH and HistobrushH cervical cytology brushes; B, CerviSoftH and HistobrushH
cytology brush tips.
doi:10.1371/journal.pone.0026395.g001
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tions, and differences between the groups were compared using
Yate’s corrected Chi-square analysis. Differences in sensitivities
and specificities were compared using the z-test. Statistical analyses
were performed using SigmaStat 2.03 software (SPSS Inc.,
Chicago, IL). Level of significance was set at p,0.05.
Results
Twenty-eight patients were enrolled in the study: 23 males and
5 females. Of 28 patients enrolled, 23 were referred for suspicious
mucosal lesions only, and 5 were referred for evaluation of
cutaneous lesions who were then noted to have mucosal
involvement on examination. Clinical and demographic charac-
teristics of the cohort are summarized in table 1. Median age was
48 years (range 16–87 years), and median duration of exposure in
the risk area was 7.5 years (range 2 days–75 years). Median
duration of illness was 25.5 months (range 1 month–20 years). Of
28 patients enrolled, 15 (54%) had a past history of CL, and 4
(14%) had old scars suspicious for past CL, but no previous
definitive diagnosis (Table 1). Of 23 patients diagnosed with ML, 4
had intercurrent cutaneous leishmaniasis.
Performance characteristics of each tested assay are summa-
rized in table 2. Biopsy PCR was 95.7% sensitive [95% CI 87.4–
100%], and 100% specific, with pooled cytology brush PCR
demonstrating 95.7% [95% CI 87.4–100%] sensitivity and 90%
[95% CI 71.4–100%] specificity. Sensitivity and specificity of
CervisoftH brush PCR were 95.7% and 90%, while HistobrushH
PCR demonstrated sensitivity of 91.3% [95% CI 79.8–100%],
and specificity of 90% [95% CI 71.4–100%]. Compared to
cytology brush PCR, traditional biopsy with histopathology and
LST had poorer performance characteristics with sensitivities of
21.7% [95% CI 4.9–38.5%] (p,0.001) and 69.6% [95% CI 50.8–
88.4%] (p=0.016), respectively [Table 2]. Expanding the
definition of biopsy with histopathological diagnosis to include
granulomatous inflammation, rather than strictly to the presence
of visible amastigotes, increased the sensitivity of biopsy with
histopathology to 71.4% [95% CI 52.9–89.9%], which was still
inferior to cytology brush PCR or biopsy PCR (p=0.024).
Subjective tolerability of the CerviSoftH brush was superior to
that of the HistobrushH, as it was reported to cause less discomfort
and was softer on the mucosa, particularly in the nose. All healthy
control volunteers had negative CerviSoftH and HistobrushH
cytology brush PCR.
Of 23 patients with ML, PCR-based assays led to species
identification in 7. Represented causative species included: L. (V.)
braziliensis, 4 patients; and L. (V.) peruviana, 3 patients. There were
no cases of L. (V.) guyanensis or L. (V.) lainsoni identified (Table 3).
Discussion
We have demonstrated that Leishmania (Viannia) kDNA can be
detected in non-invasive cytology brush specimens for the
diagnosis of ML. PCR of non-invasive cytology brush specimens
had a comparable performance to PCR of biopsy specimens, and
was superior to either conventional biopsy with histopathology or
LST. Compared to biopsy, non-invasive cytology brushes are
easier to obtain, require no technical expertise or anesthesia, cause
no discomfort to the patient, do not carry risks of bleeding or
infection, and obviate the need for sharps, sharps biosafety
disposal, or concerns regarding needle stick injuries in the health
care worker. Unlike biopsies, cytology brush specimens can be
easily collected in the field and transported back to a reference
center for testing. Thus, our data represent an advance in the
approach to diagnostic testing in ML that will benefit the patient
and health care worker alike.
Although PCR of biopsy and brush specimens were highly
sensitive and specific, there may have been 1 patient with known
previously treated CL (1990) and ML (1992), and new isolated
involvement of the buccal mucosa with no other focus of infection,
who was a biological false positive. This patient had PAS-positive
bodies on histopathology suspicious for Paracoccidioides braziliensis,
but also had a buccal mucosa biopsy and cytology brushes that
were positive for L. (Viannia) kDNA by PCR. It is therefore
possible that this patient had detectable amounts of persistent
parasite DNA in the mucosa and new infection with Paracoccidioides
braziliensis. Alternatively, the patient may have had active infection
with both paracoccidioidomycosis and leishmaniasis. In any case,
this patient highlights the need for non-invasive multiplex assays
that can differentiate between common causes of mucosal lesions
in the tropics. Although the patient fulfilled reference criteria for a
diagnosis of ML, the uncertainty surrounding the diagnosis given
the histopathology also suggests that further refinements to the
cytology brush method, possibly including a quantitative compo-
nent, are warranted.
Leishmania kDNA has been detected in the normal mucosa of
Latin American patients with CL [9], which raises the possibility
that detectable kDNA in the mucosa does not necessarily reflect
ML. While it is possible that patients in our series merely had
detectable kDNA in the mucosa, and not necessarily true ML, that
they all had clinical evidence of ML (ie, mucosal lesions) and
fulfilled a consensus reference standard for diagnosis argues
against this possibility. However, in one patient with confirmed
CL (by smear and culture of skin lesion aspirate) and erythematous
nasal mucosa, a diagnosis of ML was made based on positive nasal
biopsy PCR, cytology brush PCR, and LST, despite normal nasal
septal histopathology. It is possible that this patient simply had
detectable kDNA in the mucosa by multiple means, thus fulfilling
reference standard criteria for diagnosis, but no true ML. Given
the paucity of data surrounding treatment outcomes on patients
like this who have CL and detectable kDNA in the mucosa, we
erred on the side of caution and implemented a 28-day ML
treatment regimen rather than a 21-day CL regimen. Prospective
testing of CL patients with normal mucosa by nasal and buccal
cytology brush PCR in our center may be indicated to better
inform management of this unique situation. Regardless of how
the mucosa is labeled histopathologically, treatment of detectable
kDNA in the mucosa of CL patients with a ML regimen is likely
warranted until further data, which inform our understanding of
mucosal dissemination, are accrued.
Species identification is important in countries like Peru where
several members of the L. Viannia subgenus are co-endemic and
portend different prognoses and response to therapy [4]. L. (V).
braziliensis is historically the most well represented causative species
in ML [2,4,5]. We have demonstrated that related species
including L. (V). peruviana are implicated in mucosal disease as
well. Case-report level data implicating non-braziliensis sub-
species in ML is also mounting [2,5,27,28]. Further optimization
of direct-cytology brush species identification is required. As
genomic targets were used for species identification PCR and
RFLP assays (rather than the kinetoplast target used for the
diagnostic PCR), enhanced collection of higher concentrations of
amastigotes or parasite DNA from the lesion by additional
revolutions of the brush may improve the yield.
In summary, we have demonstrated that cytology brush PCR
using CerviSoftH and HistobrushH cervical cytology brushes is
adequate for the diagnosis of ML though identification of causative
species requires further optimization. We have further demon-
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Age, Sex Lesion Location Intercurrent CL* LST Histopathology PCR Biopsy PCR Brush**
60, M1 NS No Pos Lymphoeosinophilic infiltrate Pos Pos
46, M" NS No Neg Granulomatous inflammation Pos Pos
62, F NS No Neg Lymphoplasmo-histiocytosis Pos Pos
68, M NS Yes Neg Lymphoeosinophilic infiltrate Pos Pos{
66, M1 NS No Pos Parasitic granuloma with amastigotes Pos Pos
57, M Canthus Yes Pos Granulomatous inflammation with
amastigotes present
Pos Pos
36, M NS Yes Pos Normal cartilage Pos Pos
49, F" NS No Neg Polymorphonuclear lymphocytic infiltrate Pos Pos
75, F NS Yes Pos Lymphocytic infiltrate Pos Pos
16, M NS No Pos Parasitic granuloma with amastigotes Pos Pos
38, M1 Buccal No Neg PAS-positive bodies suspicious for
Paracoccidioides braziliensis infection
Pos Pos
31, M1 Hard Palate No Neg Granulomatous inflammation Pos Pos
87, M1 Buccal No Neg Epidermoid carcinoma Neg Neg
52, M1 NS No (stasis ulcers) Pos Granulomatous inflammation Pos Pos
63, M" NS No Pos Granulomatous inflammation Pos Pos
32, M1 NS No Pos Granulomatous inflammation Pos Neg
19, M NS No Neg Perivascular eosinophilic infiltrate Neg Neg
41, M Hard Palate No Pos Granulomatous inflammation Pos Pos
40, M1 NS No Neg Granulomatous inflammation Neg Pos
20, F1 NS No Pos Granulomatous inflammation Pos Pos
50, M1 NS No Pos Granulomatous inflammation Neg Pos
47, M1 NS No Pos Parasitic granuloma with amastigotes Pos Pos
62, F" NS No Neg Acute and chronic inflammatory infiltrate Neg Neg
43, M1 NS No Pos Parasitic granuloma with amastigotes Pos Pos
62, M NS No Neg Granulomatous inflammation Neg Neg
35, M1 NS No Neg Granulomatous inflammation Pos Pos
55, M1 NS No Pos Granulomatous inflammation Pos Pos
23, M1 NS No Pos Epithelial hyperplasia and necrosis Pos Pos
*Intercurrent CL confirmed by smear or culture of cutaneous lesion specimens.
**All 5 control volunteers had negative cytology brush specimens.
{CerviSoftH and HistobrushH PCR demonstrated 97% concordance; in 1 patient, CerviSoftH PCR was positive and HistobrushH PCR was negative.
1Patient with known previous CL on history.
"Patient with scars suspicious to be healed CL but no definitive history of diagnosis.
Abbreviations: CL, cutaneous leishmaniasis; F, female; LST, leishmanin skin test; M, male; Neg, negative; NS, nasal septum; Pos, positive.
doi:10.1371/journal.pone.0026395.t001
Table 2. Analysis of 5 Diagnostic Tests used in the Evaluation of 28 Patients with Suspected Mucosal Leishmaniasis.
Assay Number Positive Number Negative Sensitivity (%) Specificity (%) PPV (%) NPV (%)
kDNA PCR of Biopsy Specimen 22 6 95.7 100.0 100.0 83.3
kDNA PCR of CerviSoftH
brushes
23 10* 95.7 90.0 95.7 90.0
kDNA PCR of HistobrushH
brushes
22 11* 91.3 90.0 95.5 81.8
LST 16 12 69.6 100.0 100.0 41.7
Biopsy with Histopathology 5 23 21.7 100.0 100.0 21.7
*includes nasal and buccal specimens from 5 healthy control volunteers.
Abbreviations: LST, leishmanin skin test; NPV, negative predictive value; PPV, positive predictive value.
doi:10.1371/journal.pone.0026395.t002
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histopathology. Cytology brush PCR offers numerous practical
advantages over biopsy PCR including simplicity, tolerability, and
cost efficiency due to the lack of need for highly trained personnel
to collect the specimen, anesthesia, sterile biopsy instruments, and
sharps biohazard disposal and precautions. At just 30–50 cents
(US) per cytology brush, this novel diagnostic specimen is practical
and comparatively affordable. It can be transported easily to a
reference center for diagnostic testing and is likely appropriate for
field situations. Future field studies are indicated, as are studies
that aim to differentiate between common causes of mucosal
lesions in the tropics using this simple non-invasive specimen.
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Table 3. Species identification from 2 sets of specimens out
of 16 PCR-positive lesions subsequently tested with PCR-
based assays targeting the mannose phosphate isomerase,
cysteine proteinase B, heat shock protein 70, and gp63 genes.
Leishmania Species Number (% of those tested)
L. (V.) braziliensis 4 (25%)
L. (V.) guyanensis 0
L. (V.) peruviana 3 (19%)
Not identifiable 9 (56%)
Not tested* 12
*Only specimens with sufficient amplifiable DNA from the kDNA PCR of
cytology brushes were selected for direct clinical specimen PCR.
doi:10.1371/journal.pone.0026395.t003
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